Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.

ABSTRACT:

Background

Pancreatic cancer has a dismal prognosis. One reason is resistance to cytotoxic drugs. Molecularly matched therapies might overcome this resistance but the best approach to identify those patients who may benefit is unknown. Therefore, we sought to evaluate a molecularly guided treatment approach.

Materials and methods

We retrospectively analyzed the clinical outcome and mutational status of patients with pancreatic cancer who received molecular profiling at the West German Cancer Center Essen from 2016 to 2021. We carried out a 47-gene DNA next-generation sequencing (NGS) panel. Furthermore, we assessed microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status and, sequentially and only in case of KRAS wild-type, gene fusions via RNA-based NGS

SUBMITTER: Reissig TM 

PROVIDER: S-EPMC10265614 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature